<?xml version="1.0" encoding="UTF-8"?>
<p id="p0445">Identifying or developing novel drug treatment options as soon as possible is critical for the response to the SARS-CoV-2 outbreak. Based on the structural information of clinical effective medicines for SARS-CoV-2, Liu et al. predicted 10 commercial medicines which may function as inhibitors of SARS-CoV-2, including colistin, valrubicin, icatibant, bepotastine, epirubicin, etc. Some of these may be more resistant to viral mutation than lopinavir/ritonavir [
 <xref rid="bib133" ref-type="bibr">133</xref>]. Stebbing et al. suggested that baricitinib may reduce both the viral entry and inflammation [
 <xref rid="bib134" ref-type="bibr">134</xref>].
</p>
